For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG Patient Representative Bob Taylor discusses the importance of having somebody, that's not the clinical researcher, representing what patients care about and considering the interests of the patients and their family in clinical trial design.
CCTG has been awarded $1,303,560 from the Fall 2019 CIHR Project Grant competition, a program that helps advance health-related research. The funds will support the Canadian contribution to the ME15 international trial, investigating use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient - Larger margins result in disfigurement, wound discomfort, and time away from work and, if positive, will change practice in Canada and around the world.
The Canadian Cancer Trials Group is seeking nominations for the 2020 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Genitourinary Disease Site Committee Executives as well as Supportive Care Committee.
As 2020 begins, I wanted to take a moment to reflect on the hard work and accomplishments of our network of researchers and collaborators, both nationally and internationally, over the past year.
This year we supported 67 ongoing trials while working with our scientific network to activate 15 new trials of which 10 are being led by CCTG. This includes the IND234 trial that opened three new treatment arms this year—IND234 is the first trial to evaluate a precision medicine approach for patients with advanced prostate cancer using liquid biopsies for genomic testing.
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
